Top 10 GLP-1 Telehealth Providers Compared: Pricing, Brand vs Compound, Speed (2026)

Medical disclaimer: This article is informational and is not medical advice. GLP-1 receptor agonists carry risks including pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors. Talk to a licensed clinician before starting, switching, or stopping any GLP-1 medication.

The GLP-1 telehealth market reorganized fast in 2024-26. The FDA resolved the tirzepatide shortage on December 19, 2024, then declared the semaglutide shortage over on February 21, 2025 — removing the shortage-based legal cover that had let compounders make near-copies of Wegovy, Ozempic, Zepbound, and Mounjaro.

On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List outright, finding no clinical need for outsourcing facilities to compound them from bulk substances. The comment period was extended to July 30, 2026 and has now closed; as of this writing the FDA has not issued a final rule. Meanwhile FDA has said it will not enforce against 503A pharmacies filling four or fewer prescriptions of a compounded drug per month for a documented patient-specific reason — a narrow lane, not the broad "shortage" exception compounders relied on through 2024, per Foley & Lardner's 2026 compounder policy briefing.

Below: 10 providers ranked on prescriber model, drug source, monthly cost, ship speed, BMI rules, and support. Pricing checked directly against provider websites and official price guides in August 2026.

At a glance: 10 GLP-1 telehealth providers compared

Rank	Provider	Brand or Compound	Monthly Cost (cash)	Verdict
1	LillyDirect / NovoCare	Brand only (mfr direct)	$149-$599	Best price-to-trust ratio
2	Sequence (WW Clinic)	Brand only	$25-$149 program + drug	Best wrap for brand patients
3	Ro (Roman Health)	Brand + insurance fight	$149 + drug	Best for insurance navigation
4	Found	Brand or compound + insurance	$49-$199 + drug	Best behavioral coaching
5	Calibrate	Brand-focused	$199 + drug	Best maintenance plan
6	Mochi Health	Compounded (flat)	$79 + $99-$199	Best flat-rate compounded
7	Henry Meds	Compounded	$179-$297	Established compounded option
8	EllieMD	Compounded	$229-$379	Microdose compounded
9	WeightCare	Compounded	$333-$499	New compounded entrant
10	Hims & Hers	Brand only (post-settlement)	$349-$499	Watch — recently pivoted off compounding

---

1. LillyDirect / NovoCare Pharmacy — Manufacturer Direct (Verdict: Best price-to-trust ratio)

The two drug makers cut out the telehealth middlemen in 2024-25 and cut prices again in December 2025. LillyDirect Zepbound single-dose vials now run $299/mo for 2.5 mg, $399/mo for 5 mg, and $449/mo for 7.5-15 mg — but only if you refill within 45 days of your last delivery. Miss that window and the higher doses jump to standard self-pay pricing ($599 to $1,049/mo). NovoCare Pharmacy's official price guide lists the Wegovy injection pen at $349/mo for 0.25-2.4 mg and $399/mo for the 7.2 mg HD dose (with a $199/mo intro rate on the two lowest doses for new patients' first two fills), and the oral Wegovy pill at $149/mo for the 1.5 mg and 4 mg starter doses, rising to $299/mo at 9 mg and 25 mg.

Prescribers are independent telehealth networks (FORM, 9amHealth, Sesame) that route prescriptions to the manufacturer pharmacy. Most use NPs and PAs supervised by MDs.

BMI rules follow the label: ≥30, or ≥27 with a comorbidity. Shipping is 5-7 business days, slower than compounders but guaranteed FDA-approved product. No coaching included.

Best for: Patients who want brand-name medication at the lowest legal cash price and don't need a wrap.

2. Sequence by WeightWatchers — Brand-Only Clinical Program (Verdict: Best wrap for brand patients)

WeightWatchers Clinic (formerly Sequence) prices its membership at $25/mo for the first 3 months on a 12-month commitment, then $74/mo — or up to $149/mo month-to-month with no commitment. Medication is billed separately, through insurance or cash. The program is brand-only post-shortage; compounded sourcing was dropped in 2025 as FDA enforcement tightened.

About half of WeightWatchers Clinic's prescribing doctors are board-certified in obesity medicine, and all complete a required training program on the newer GLP-1 medications before prescribing. Members get a care coordinator, registered dietitian access, and a fitness specialist as part of the multidisciplinary team, not an upsell.

BMI cutoffs match FDA labeling: 30+, or 27+ with one comorbidity like sleep apnea or prediabetes. Shipping speed depends on the pharmacy partner; 7-10 days is typical. Cash cost for the drug itself varies widely with dose and pharmacy — get a specific quote before enrolling.

Best for: Patients with cardiovascular history, prediabetes, or sleep apnea who need actual medical supervision.

3. Ro (Roman Health) — Brand + Insurance Navigation (Verdict: Best for insurance navigation)

Ro Body charges $39 for month one then $149/mo, dropping to $74/mo on a 12-month prepay ($89/mo on 6-month, $99/mo on 3-month). Medication is billed separately: Wegovy pill at $149-$299/mo depending on dose, Wegovy pen at $199/mo (intro rate, regularly $349) for the lowest doses up to $399/mo for the HD dose, and Zepbound vials at $299-$449/mo.

Prescribers are NPs and PAs in Ro's network. The standout feature is the insurance concierge — Ro files prior authorizations and handles appeals on your behalf. Large-employer coverage for GLP-1s has ticked up in 2025-26, though small-group and individual-market coverage remains inconsistent.

BMI 27+ with comorbidity or 30+ for cash patients. Shipping is 3-5 business days via Ro Pharmacy. Limited coaching — mostly app-based check-ins.

Best for: Patients who suspect they have insurance coverage but can't get past the prior authorization wall on their own.

4. Found — Brand + Behavioral Coaching (Verdict: Best behavioral coaching)

Found's PLUS membership runs $199 per 30 days, auto-renewing until canceled; members with in-network insurance often pay under $30 per clinical visit. Medication is billed on top of the membership: compounded GLP-1s start around $99/mo, non-GLP-1 weight-loss medications start around $49/mo, and brand-name Wegovy or Zepbound run $650/mo or more without insurance — Found advertises savings of $100+/mo on compounded drugs with a prepaid annual plan.

Prescribers are NPs and PAs licensed state-by-state. The intake includes screening for binge eating disorder and night eating syndrome, both of which can complicate GLP-1 response and are easy to miss elsewhere.

BMI rules match label. Shipping speed varies because Found uses retail pharmacies (your insurance's preferred network) when possible for brand drugs.

Best for: First-time GLP-1 patients who want behavior change built into the program, not bolted on.

5. Calibrate — Brand-Focused Metabolic Program (Verdict: Best maintenance plan)

Calibrate charges $199/mo with a 3-month minimum commitment ($597 upfront), then month-to-month. Most commercially insured members pay a fraction of that for the branded GLP-1 itself after meeting their deductible; cash-pay patients add drug cost on top.

Prescribers are NPs supervised by MDs. The differentiator is the maintenance protocol — Calibrate runs a structured post-medication program aimed at preventing regain. That's a real problem: a 2026 systematic review in eClinicalMedicine found patients regain about 60% of lost weight in the year after stopping a GLP-1, with regain modeled to plateau around 75% of the weight lost long-term. Most competing programs have no structured off-ramp at all.

BMI 27+ with comorbidity or 30+. Shipping via retail pharmacy network, 5-7 days typical. Includes 1:1 coaching with a registered dietitian, monthly lab orders, and a structured 12-month curriculum.

Best for: Patients planning to hit goal weight and come off medication — not stay on forever.

6. Mochi Health — Compounded Semaglutide (Flat Rate) (Verdict: Best flat-rate compounded)

Mochi charges $79/mo for membership ($39 first-month promo in eligible states) plus a flat $99/mo for compounded semaglutide or $199/mo for compounded tirzepatide, at every dose. No tier creep. Delivery is 24-72 hours, which beats any brand option.

Prescribers are NPs and PAs. The compounded sourcing operates under 503A pharmacy partnerships citing "personalization" — typically B12-added formulations or specific concentrations not commercially available. Whether that survives the FDA's April 30, 2026 503B bulks proposal and the tightened enforcement discretion around it is genuinely unclear.

BMI 27+ standard. Coaching is minimal — health tracking app, no live RD. All-in cost: $178/mo for semaglutide or $278/mo for tirzepatide, with no insurance billing.

Best for: Patients who tolerate GLP-1s well, want speed and flat pricing, and accept the regulatory risk.

7. Henry Meds — Compounded GLP-1 (Verdict: Established compounded option)

Henry Meds prices injectable compounded semaglutide at $297/mo month-to-month, dropping to $247/mo on a 6-month prepay or $197/mo on a 12-month prepay; a sublingual (oral drop) version runs $179-$249/mo depending on tier. Henry does not offer injectable tirzepatide — only oral dissolving tablets, sold as a 3-month supply for $1,047 ($891 prepaid), with no published month-to-month rate.

Prescribers are NPs and PAs licensed in all 50 states. Henry has been in the compounded space longest and uses 503A partner pharmacies with publicly disclosed inspection records. Ship time is 24-72 hours from prescription. No insurance accepted, and no consultation fee — you pay only once a prescription is written.

BMI 27+ with comorbidity or 30+. No coaching included — pure prescription-and-ship model.

Best for: Patients comfortable on a stable maintenance dose who don't want to keep escalating.

8. EllieMD — Compounded with Microdose Option (Verdict: Microdose compounded)

EllieMD compounded semaglutide runs about $299/mo standard, billed as $897 per 12-week supply, with a lower-cost microdose option for patients who can't tolerate standard dosing. Compounded tirzepatide is priced higher. Pricing includes injection supplies and provider access; a $99 cancellation fee applies if you cancel before your prescription is approved.

Prescribers are MDs and NPs. The microdose pathway — starting below the standard 0.25 mg semaglutide dose — is a real clinical option for patients with significant GI intolerance to the standard starting dose, though there's no FDA-approved microdosing protocol and the exact share of patients who need it isn't independently documented.

BMI 27+ standard. Shipping 24-72 hours. Coaching is app-based, not 1:1. EllieMD does not accept insurance for compounded medications.

Best for: Patients with prior GI intolerance who need below-label starter doses.

9. WeightCare — Compounded Options (Verdict: New compounded entrant)

WeightCare prices its compounded programs at $499/mo month-to-month, or $997 for a 3-month standard-dose supply (about $333/mo) and $1,350 for a 3-month high-dose supply (about $450/mo), with a 6-month high-dose option at $2,150 (about $358/mo). Pricing is set per product page and changes with dose tier.

Prescribers are NPs in WeightCare's network via a HIPAA-compliant telehealth intake. Shipping details and pharmacy partner disclosure are less publicly documented than at Mochi or Henry — worth confirming directly before enrolling. The company is smaller than the established compounded players, which can mean tighter prescriber follow-up but also less infrastructure if your state's compounding rules change.

BMI 27+ with comorbidity or 30+ typical for compounded programs. No insurance billing.

Best for: Patients comparison-shopping smaller compounded shops, with pricing confirmed directly before enrolling.

10. Hims & Hers — Pivoted to Brand-Only After Novo Settlement (Verdict: Watch — recently pivoted off compounding)

Hims & Hers launched a compounded oral semaglutide pill on February 5, 2026 at $49 for the first month, $99/mo after. The launch drew immediate regulatory heat: HHS's general counsel referred the product to the DOJ within a day, and Novo Nordisk sued Hims for patent infringement on February 9, 2026, sending Hims shares down 18%. Hims pulled the pill under the pressure.

The two companies settled on March 9, 2026: Novo dropped the suit and Hims agreed to stop marketing compounded GLP-1s and become a Novo distribution partner instead, selling FDA-approved Ozempic and Wegovy at the same self-pay pricing other telehealth platforms charge — Wegovy at $349/mo, Ozempic at $349/mo for the 0.25-1 mg doses and $499/mo at 2 mg. Existing compounded-semaglutide patients received transition notices in mid-April 2026 as the compounded program wound down for good.

Prescribers are NPs in Hims's network. The company's drug sourcing has been genuinely volatile over the past 18 months — a full compounding launch, a lawsuit, a reversal, and a brand-pricing pivot inside of five weeks.

BMI 27+ with comorbidity or 30+. Shipping 3-5 days.

Best for: Patients who want Hims's app experience but with brand-name medication now that compounding is off the table. New patients should confirm current pricing directly, given how recently the model changed.

---

How We Ranked

GLP-1 rankings (medications, providers, comparisons) combine:

1. Clinical evidence: SUSTAIN, STEP, PIONEER, and SOUL trial data, FDA prescribing information, and CMS coverage criteria.
2. Patient-reported patterns: monitoring r/Semaglutide, r/Tirzepatide, and r/GLP1 for recurring reports on supply, compounding-pharmacy experiences, and side effects.
3. Direct verification: pricing, BMI criteria, shipping claims, and pharmacy-partner disclosures checked against each provider's own website and official price guides at time of publication.

What we never accept: paid placement, compounding-pharmacy referral fees, or sponsorships that influence brand recommendations. Disclosure: affiliate links to vitamin and HSA-related resources appear elsewhere on the site and never affect medication or provider rankings.

Update cadence: each provider quarterly; pricing on demand. Last-updated at top. Email research@theglp1daily.com.

Frequently Asked Questions

1. What is the FDA's current stance on compounded GLP-1?

The tirzepatide shortage was declared resolved in December 2024 and the semaglutide shortage in February 2025, removing the broad legal basis for compounding near-copies. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely; the comment period closed July 30, 2026, and a final decision has not yet been issued. Narrow 503A patient-specific exceptions remain — FDA has said it won't enforce against pharmacies filling four or fewer prescriptions of a compounded drug per month for a documented, individualized reason — but cost savings alone is not sufficient justification.

2. Does insurance cover GLP-1 telehealth?

For type 2 diabetes diagnoses, most commercial plans cover Ozempic or Mounjaro with prior authorization. For obesity without diabetes, employer coverage has held roughly flat to slightly up — about 36% of employers covered GLP-1s for weight loss in 2026, versus 34% in 2024, with large employers far more likely to offer it than small ones. Most plans that do cover GLP-1s still require prior authorization. Medicare does not cover GLP-1s for obesity alone. Ro and Found have the strongest insurance navigation; LillyDirect and NovoCare are cash-only.

3. What are the BMI cutoffs to qualify?

FDA labeling for Wegovy and Zepbound requires BMI ≥30, or ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea). Some compounded providers prescribe below these thresholds, which is off-label.

4. What are the main side effects?

Nausea, vomiting, diarrhea, and constipation affect 40-60% of patients in the first 8 weeks per Wegovy and Zepbound labels. Serious risks include pancreatitis, gallbladder disease, and a boxed warning for medullary thyroid carcinoma in patients with MTC or MEN-2 history. Discontinue for severe abdominal pain.

5. What happens when I stop the medication?

A 2026 systematic review and meta-regression in eClinicalMedicine (six RCTs, 3,236 participants) found patients regain roughly 60% of lost weight within a year of stopping a GLP-1, with modeled long-term regain plateauing around 75% of what was lost — meaning some of the benefit does persist, but most does not without a structured taper or maintenance plan. Calibrate has the most explicit post-medication protocol; Sequence and Found include some taper planning. Bargain-tier compounded programs generally have no off-ramp.

Bottom line and related reading

Brand-name cash pay: LillyDirect or NovoCare. Insurance navigation: Ro or Found. Real coaching wrap: Sequence or Calibrate. Compounded remains available through Mochi, Henry, EllieMD, and WeightCare, but the FDA's pending 503B bulks decision means the cost arbitrage could disappear with little notice — Hims & Hers' five-week round trip from compounded launch to lawsuit to brand-only pivot in February-March 2026 is the cautionary example. Pick on clinical fit and pharmacy-partner transparency, not price alone.

Related reading

• Best GLP-1 Telehealth Programs of 2026 [Ranked by Cost & Care]
• Compounded GLP-1 After the FDA Crackdown [2026]
• Eli Lilly Direct Self-Pay Pricing Tracker [2026]

-- The GLP-1 Daily Team